Literature DB >> 7550232

Four novel mutations underlying mild or intermediate forms of alpha-L-iduronidase deficiency (MPS IS and MPS IH/S).

P T Tieu1, G Bach, A Matynia, M Hwang, E F Neufeld.   

Abstract

The alpha-L-iduronidase deficiency diseases (Mucopolysaccharidosis I) cover a spectrum of clinical severity ranging from the very severe (Hurler syndrome, MPS IH) through an intermediate (Hurler/Scheie syndrome, MPS IH/S) to a relatively mild form (Scheie syndrome, MPS IS). Numerous mutations of the gene encoding alpha-L-iduronidase (IDUA) are known in Hurler syndrome, but only three in the other disorders. We report on novel mutations of the IDUA gene in one patient with the Scheie syndrome and in three patients with the Hurler/Scheie syndrome. The novel mutations, all single base changes, encoded the substitutions R492P (Scheie), and X654G, P496L, and L490P (Hurler/Scheie). The L490P mutation was apparently homozygous, whereas each of the others was found in compound heterozygosity with a Hurler mutation. The deleterious nature of the mutations was confirmed by absence of enzyme activity upon transfection of the corresponding mutagenized cDNAs into Cos-1 cells. These results provide additional information for genotype-phenotype correlations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7550232     DOI: 10.1002/humu.1380060111

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

1.  Structural study on mutant alpha-L-iduronidases: insight into mucopolysaccharidosis type I.

Authors:  Kanako Sugawara; Seiji Saito; Kazuki Ohno; Torayuki Okuyama; Hitoshi Sakuraba
Journal:  J Hum Genet       Date:  2008-03-14       Impact factor: 3.172

2.  Molecular genetic defect underlying alpha-L-iduronidase pseudodeficiency.

Authors:  E L Aronovich; D Pan; C B Whitley
Journal:  Am J Hum Genet       Date:  1996-01       Impact factor: 11.025

3.  Cargo proteins of plasma astrocyte-derived exosomes in Alzheimer's disease.

Authors:  Edward J Goetzl; Maja Mustapic; Dimitrios Kapogiannis; Erez Eitan; Irina V Lobach; Laura Goetzl; Janice B Schwartz; Bruce L Miller
Journal:  FASEB J       Date:  2016-08-10       Impact factor: 5.191

Review 4.  Cell and Gene Therapies for Mucopolysaccharidoses: Base Editing and Therapeutic Delivery to the CNS.

Authors:  Chloe L Christensen; Rhea E Ashmead; Francis Y M Choy
Journal:  Diseases       Date:  2019-06-26

5.  "Missing mutations" in MPS I: Identification of two novel copy number variations by an IDUA-specific in house MLPA assay.

Authors:  Amir Jahic; Sven Günther; Nicole Muschol; Barbro Fossøy Stadheim; Øivind Braaten; Hanne Kjensli Hyldebrandt; Gé-Ann Kuiper; Karen Tylee; Frits A Wijburg; Christian Beetz
Journal:  Mol Genet Genomic Med       Date:  2019-07-18       Impact factor: 2.183

6.  Mucopolysaccharidosis Type I in the Russian Federation and Other Republics of the Former Soviet Union: Molecular Genetic Analysis and Epidemiology.

Authors:  E Yu Voskoboeva; T M Bookina; A N Semyachkina; S V Mikhaylova; N D Vashakmadze; G V Baydakova; E Yu Zakharova; S I Kutsev
Journal:  Front Mol Biosci       Date:  2022-01-24

Review 7.  Mucopolysaccharidosis Type I.

Authors:  Francyne Kubaski; Fabiano de Oliveira Poswar; Kristiane Michelin-Tirelli; Ursula da Silveira Matte; Dafne D Horovitz; Anneliese Lopes Barth; Guilherme Baldo; Filippo Vairo; Roberto Giugliani
Journal:  Diagnostics (Basel)       Date:  2020-03-16
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.